Table 1.
Risk of HBV Reactivation by Drug Type
| Level of Risk | HBsAg(+) | HBsAg(‐) and anti‐HBc(+) | Antiviral Therapy |
|---|---|---|---|
| Very high risk | B‐cell depleting agents (rituximab and ofatumumab) | B‐cell depleting agents (rituximab and ofatumumab) | Prophylaxis |
| High risk | Anthracycline derivatives (systemic chemotherapy and TACE) | Anthracycline derivatives (systemic chemotherapy and TACE) | Prophylaxis |
| Corticosteroids (> 4 weeks) | |||
| Intermediate risk | Anti‐TNF agents | Anti‐TNF agents | Prophylaxis or preemptive monitoring |
| Other biologic agents (cytokine and integrin inhibitors) | Other biologic agents (cytokine and integrin inhibitors) | ||
| Corticosteroids (> 4 weeks) | |||
| Low risk | Corticosteroids (< 4 weeks) | Corticosteroids (< 4 weeks) | No prophylaxis indicated |
| Azathioprine or 6‐MP | Azathioprine or 6‐MP | ||
| Methotrexate | Methotrexate |